Fresenius SE & Co. KGaA (FRE) AI Stock Analysis

• Market Cap: €26.22B
• Dividend Yield: 2.15%
• Average Volume (3M): 836.14K
• Price to Earnings (P/E): 23.7
• Beta (1Y): 0.73
• Revenue Growth: -0.59%
• EPS Growth: N/A
• Country: DE
• Employees: 175,202
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Care Facilities
• EPS (TTM): 0.86
• Shares Outstanding: 563,237,300
• 10 Day Avg. Volume: 816,859
• 30 Day Avg. Volume: 836,139
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €50.06
• Price Target Upside: 7.42% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 69 Neutral
• Price Target: €51.00 ▲(9.44% Upside)

Fresenius SE & Co. KGaA's overall stock score is driven by strong technical analysis, indicating bullish momentum, despite overbought signals. Financial performance shows robust revenue growth but highlights challenges in profitability and cash flow. The valuation suggests the stock might be overvalued, with a moderate dividend yield.

Fresenius SE & Co. KGaA Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA is a global healthcare group based in Germany, operating in various sectors including healthcare services, medical devices, and pharmaceuticals. The company is organized into several business segments, primarily Fresenius Medical Care, which focuses on dialysis products and services; Fresenius Kabi, which specializes in intravenous therapies and clinical nutrition; and Fresenius Helios, which operates hospitals and outpatient facilities. Fresenius is committed to delivering high-quality healthcare solutions and is recognized for its innovation in medical technology and patient care.

How the Company Makes Money

Fresenius SE & Co. KGaA generates revenue through multiple key streams. The largest contributor is Fresenius Medical Care, which earns money from the sale of dialysis machines, consumables, and the provision of dialysis services to patients worldwide. Fresenius Kabi contributes significantly through the sale of intravenous drugs, infusion therapies, and nutritional products, often through long-term contracts with hospitals and healthcare providers. Additionally, Fresenius Helios generates revenue by operating hospitals and outpatient facilities, charging for patient services and treatments. The company also benefits from strategic partnerships with healthcare organizations, research institutions, and government agencies that enhance its service offerings and market reach, contributing to stable and diversified revenue generation.

Fresenius SE & Co. KGaA Financial Statement Overview

Summary

Fresenius SE & Co. KGaA demonstrates stable revenue growth and operational efficiency, with strong cash flow generation capabilities. However, the company faces challenges with low net income margins and ROE, suggesting potential areas for improvement in profitability. The balance sheet reflects moderate leverage and a solid equity base, positioning the company well for future growth.

Income Statement

The TTM (Trailing-Twelve-Months) gross profit margin is 24.5%, with a net profit margin of 1.9%. The revenue growth rate shows a moderate increase of 1.3% from the previous year. EBIT and EBITDA margins stand at 8.7% and 14.0%, respectively, indicating stable operational efficiency despite a slight decline in net income. However, past fluctuations in net income suggest some volatility.

Balance Sheet

The debt-to-equity ratio is 0.70, reflecting a moderate level of leverage, which is common in the industry. Return on Equity (ROE) is 2.2%, which is relatively low, indicating limited efficiency in generating profits from equity. The equity ratio is 44.9%, suggesting a stable capital structure dominated by equity.

Cash Flow

The free cash flow growth rate is 9.5%, showing positive cash flow management. The operating cash flow to net income ratio is 6.2, indicating strong cash generation relative to net income. The free cash flow to net income ratio of 3.95 further emphasizes robust cash flow productivity, despite net income variability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.23B	21.83B	22.30B	40.84B	37.52B	36.28B
Gross Profit	5.65B	5.38B	5.06B	10.72B	10.31B	10.32B
EBITDA	3.33B	2.95B	2.73B	3.09B	6.84B	7.19B
Net Income	1.13B	471.00M	-594.00M	1.37B	1.82B	1.71B
Balance Sheet
Total Assets	41.32B	43.55B	45.28B	76.42B	71.96B	66.65B
Cash, Cash Equivalents and Short-Term Investments	1.39B	2.05B	2.56B	2.35B	2.75B	2.00B
Total Debt	12.85B	13.58B	15.83B	27.76B	27.16B	25.91B
Total Liabilities	22.38B	23.26B	25.63B	44.20B	42.67B	40.62B
Stockholders Equity	18.28B	19.54B	19.00B	20.41B	19.00B	16.95B
Cash Flow
Free Cash Flow	1.24B	1.52B	3.32B	2.28B	3.03B	4.14B
Operating Cash Flow	2.21B	2.45B	4.46B	4.20B	5.08B	6.55B
Investing Cash Flow	-559.00M	-510.00M	-3.19B	-2.61B	-2.82B	-3.01B
Financing Cash Flow	-1.51B	-2.18B	-1.38B	-1.60B	-1.45B	-3.12B

Fresenius SE & Co. KGaA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 46.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FRE, the sentiment is Positive. The current price of 46.6 is above the 20-day moving average (MA) of 44.79, above the 50-day MA of 43.11, and above the 200-day MA of 38.79, indicating a bullish trend. The MACD of 1.35 indicates Negative momentum. The RSI at 67.02 is Neutral, neither overbought nor oversold. The STOCH value of 59.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FRE.

Fresenius SE & Co. KGaA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FRE	69 Neutral	€26.22B	23.69	7.30%	2.15%	-0.59%	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
0P6S	―	€28.09B	―	-10.35%	―	―	―
0H9X	―	€12.81B	19.50	4.83%	―	―	―
0O14	―	€46.87B	16.70	10.08%	―	―	―
0NIQ	―	€12.34B	106.25	3.88%	0.45%	―	―
SEMHF	―	$61.32B	26.39	11.75%	1.70%	―	―